Romiplostim (Nplate®)


Indications for Prior Authorization

  • Chronic immune (idiopathic) thrombocytopenic purpura (ITP)

Patients must meet the following criteria for the indication(s) above:

  • Failure/adverse effects from corticosteroids, immunoglobulins, or splenectomy AND
  • Baseline platelet count of less than 30,000/ml

The Following Conditions Do Not Meet the Criteria for Use as Established by the WHA P&T Committee:

  • All non-FDA approved uses not listed in the approved indications


  • Initial dose 1 mcg/kg once weekly SC
  • Do Not Exceed: 10 mcg/kg weekly SC


  • One month initial
  • 6 months provided patient maintains platelet count between 50 and 200 x 109/L


Last review date: May 28, 2019

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.